Jeng-Shin Lee

Jeng-Shin Lee is the Senior Vice President at Rock BioMedical, Inc., where he leverages his extensive background in molecular biology and medical research. He holds an MD from National Taiwan University and a PhD in Virology from Harvard University. His academic journey includes postdoctoral fellowships at both MIT and Harvard Medical School, where he gained significant expertise in gene transfer technology and biologics development.

Before his current role, Lee served as the Chief Scientific Officer at AB Biosciences, Inc. from 2011 to 2022, and he was the Deputy Director of the Harvard Gene Therapy Initiative, where he played a crucial role in supporting multiple successful Investigational New Drug (IND) submissions targeting various diseases, including muscle disorders and cancer.124

His professional experience is complemented by a strong network within the biotechnology sector, making him a prominent figure in the field of gene and cell therapy.32